| Global retinoblastoma presentation and analysis by national income level ID Fabian, E Abdallah, SU Abdullahi, RA Abdulqader, SA Boubacar, ... JAMA oncology 6 (5), 685-695, 2020 | 261 | 2020 |
| Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children V Minard-Colin, A Aupérin, M Pillon, GAA Burke, DA Barkauskas, ... New England Journal of Medicine 382 (23), 2207-2219, 2020 | 183 | 2020 |
| CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study B Fritzsching, J Fellenberg, L Moskovszky, Z Sápi, T Krenacs, I Machado, ... Oncoimmunology 4 (3), e990800, 2015 | 121 | 2015 |
| Good prognosis of localized osteosarcoma in young patients treated with limb‐salvage surgery and chemotherapy M Hegyi, AF Semsei, Z Jakab, I Antal, J Kiss, M Szendroi, M Csoka, ... Pediatric blood & cancer 57 (3), 415-422, 2011 | 110 | 2011 |
| Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B … V Minard-Colin, A Auperin, M Pillon, A Burke, JR Anderson, ... Journal of Clinical Oncology 34 (15_suppl), 10507-10507, 2016 | 92 | 2016 |
| Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “Watch and wait” strategy after complete resection A Attarbaschi, A Beishuizen, G Mann, A Rosolen, T Mori, A Uyttebroeck, ... Annals of hematology 92, 1537-1541, 2013 | 76 | 2013 |
| Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents A Attarbaschi, E Carraro, O Abla, S Barzilai-Birenboim, S Bomken, ... haematologica 101 (12), 1581, 2016 | 70* | 2016 |
| Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia K Nemes, M Csóka, N Nagy, Á Márk, Z Váradi, T Dankó, G Kovács, ... Pathology & Oncology Research 21, 597-604, 2015 | 70 | 2015 |
| Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial L Mussolin, MC Le Deley, E Carraro, C Damm-Welk, A Attarbaschi, ... Cancers 12 (10), 2747, 2020 | 51 | 2020 |
| Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases K Mellgren, A Attarbaschi, O Abla, S Alexander, S Bomken, E Bubanska, ... Annals of hematology 95, 1295-1305, 2016 | 51 | 2016 |
| Rheumatic symptoms in childhood leukaemia and lymphoma-a ten-year retrospective study L Zombori, G Kovacs, M Csoka, B Derfalvi Pediatric Rheumatology 11, 1-5, 2013 | 49 | 2013 |
| Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma M Hegyi, A Arany, AF Semsei, K Csordas, O Eipel, A Gezsi, N Kutszegi, ... Oncotarget 8 (6), 9388, 2017 | 46 | 2017 |
| Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease–a combined tissue microarray, in vitro and in vivo study Á Márk, M Hajdu, Z Váradi, TB Sticz, N Nagy, J Csomor, L Berczi, V Varga, ... BMC cancer 13, 1-12, 2013 | 44 | 2013 |
| Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease Z Váradi, R Bánusz, J Csomor, K Kállay, E Varga, G Kertész, M Csóka OncoTargets and therapy, 521-526, 2017 | 42 | 2017 |
| The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries ID Fabian, E Abdallah, SU Abdullahi, RA Abdulqader, AA Abdulrahaman, ... The Lancet global health 10 (8), e1128-e1140, 2022 | 36 | 2022 |
| Incidence of retinoblastoma has increased: results from 40 European countries AW Stacey, R Bowman, A Foster, TT Kivelä, FL Munier, N Cassoux, ... Ophthalmology 128 (9), 1369-1371, 2021 | 36 | 2021 |
| Late immune recovery in children treated for malignant diseases GT Kovacs, O Barany, B Schlick, M Csoka, J Gado, A Ponyi, J Müller, ... Pathology & Oncology Research 14, 391-397, 2008 | 36 | 2008 |
| Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL) K Nemes, A Sebestyén, Á Márk, M Hajdu, I Kenessey, T Sticz, E Nagy, ... PLoS One 8 (4), e59335, 2013 | 33 | 2013 |
| Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. M Csoka, G Strauss, KM Debatin, G Moldenhauer Leukemia 10 (11), 1765-1772, 1996 | 33 | 1996 |
| The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy OT Eipel, K Németh, D Török, K Csordas, M Hegyi, A Ponyi, A Ferenczy, ... International journal of hematology 97, 216-222, 2013 | 31 | 2013 |
